**Name** **of** **Journal:** *World* *Journal* *of* *Gastroenterology*

**Manuscript** **NO:** 67033

**Manuscript** **Type:** MINIREVIEWS

**Treatment** **of** ***Helicobacter*** ***pylori*** **infection** **in** **the** **presence** **of** **penicillin** **allergy**

Dutta AK *et* *al*. *H.pylori* treatment in penicillin allergy

Amit Kumar Dutta, Perminder Singh Phull

**Amit** **Kumar** **Dutta,** Department of Gastroenterology, Christian Medical College, Vellore 632004, India

**Amit** **Kumar** **Dutta,** **Perminder** **Singh** **Phull,** Department of Digestive Disorders, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, United Kingdom

**Author** **contributions:** Dutta AK and Phull PS contributed equally to this work, jointly undertook the literature review; Phull PS had the idea for the review; Dutta AK wrote the first draft of the manuscript, which was revised by Phull PS; all authors have read and approved the final manuscript.

**Corresponding** **author:** **Perminder** **Singh** **Phull,** **FRCP,** **FRCPE,** **MBBS,** **MD,** **Doctor,** Department of Digestive Disorders, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen AB25 2ZN, United Kingdom. perminder.phull@nhs.scot

**Received:** April 12, 2021

**Revised:** June 17, 2021

**Accepted:** **November 15, 2021**

**Published** **online:**

**Abstract**

Therapy of *Helicobacter* *pylori* (*H.pylori*) requires a combination of antibiotics together with an acid suppressing agent; most treatment regimens include Amoxicillin as one of the antibiotics, which is an important constituent as resistance to it is low. However, allergies to the penicillin group of antibiotics are not uncommon, and treating *H.pylori* infection in such individuals can be challenging due to the restricted choice of regimens. The aim of this review is to summarise the evidence for therapeutic options in patients with *H.pylori* infection and penicillin allergy. A literature search was conducted in PubMed for English language publications using the key words ‘Helicobacter’ and ‘treatment’ or ‘therapy‘ and ‘penicillin’ or ‘beta-lactam’ and ‘allergy’ or ‘anaphylaxis’. Eighteen studies were identified that specifically evaluated *H.pylori* treatment success in penicillin allergic patients. The number of subjects in most of them was low and many were retrospective, uncontrolled, single cohort studies. The most effective option for first-line treatment appears to be Bismuth-based quadruple therapy for 10-14 d. The evidence supports second-line treatment with Levoflaxacin-based triple therapy for 10 d. Patients with persistent *H.pylori* infection after 2 treatment courses should be considered for testing to confirm penicillin allergy. Further treatment should be guided by the results of *H.pylori* culture and sensitivity testing.

**Key** **Words:** *Helicobacter* *pylori*; Infection; Treatment; Penicillin-allergy; Stomach; Duodenum

Dutta AK, Phull PS. Treatment of *Helicobacter* *pylori* infection in the presence of penicillin allergy. *World* *J* *Gastroenterol* 2021; In press

**Core** **Tip:** Penicillin allergy is a not uncommon occurrence and treating *Helicobacter* *pylori* infection in such individuals can be challenging. This review highlights the lack of high-quality studies to help guide management strategies. Recommendations have been made based on the limited data, but it would be important to monitor the success of treatment regimens and use what can be demonstrated to be effective locally.

**INTRODUCTION**

Infection with *Helicobacter* *pylori* (*H.pylori*) is prevalent worldwide with about half of world’s population estimated to be affected by this gram negative spiral bacterium[1]. The organism is causally implicated in the pathogenesis of peptic ulcer disease[2] and gastric adenocarcinoma[3]. Guidelines for the management of *H.pylori* infection have been published by a number of national societies and organisations[4-7].

Therapy of *H.pylori* requires a combination of antibiotics together with an acid suppressing agent (proton-pump inhibitor, PPI); most treatment regimens include Amoxicillin as one of the antibiotics, which is a particularly important constituent as resistance to it is low[8]. However, allergies to the penicillin group of antibiotics are reported in 5% to 15% of patients in developed countries[9] and, consequently, the treatment options in individuals allergic to penicillin are significantly restricted.

In this review we summarise the available evidence for therapeutic options in patients with *H.pylori* infection and penicillin allergy.

**literature search**

A literature search was conducted in PubMed using the key words ‘Helicobacter’ and ‘treatment’ or ‘therapy‘ and ‘penicillin’ or ‘beta-lactam’ and ‘allergy’ or ‘anaphylaxis’ for English language publications from database commencement until January 31, 2021. Of the 77 publications identified, 18 studies were included in the review (48 were excluded as not relevant, and 11 were review articles)[10-27].

**EVIDENCE** **FOR** **TREATMENT** **OF** ***H.PYLORI*** **INFECTION** **IN** **THE** **PRESENCE** **OF** **PENICILLIN** **ALLERGY**

Data from studies specifically targeting penicillin allergic patients (Table 1). Considering the large volume of publications on *H.pylori* therapy, there is relatively little data on treatment of this bacterium in penicillin allergic individuals. A summary of data available from the 18 identified studies is shown in the Table. It should be noted that the number of subjects included in most of them is quite low and many are retrospective, uncontrolled, single cohort studies. All results discussed below are presented on an intention-to-treat basis.

***First line therapy***

**Dual therapy:** Prach *et* *al*[10] reported 100% treatment success with a 14 d combination of Omeprazole and Clarithromycin; however, this was only in 3 patients.

**Triple therapy:** The success rate with the 7 d PPI-Clarithromycin-Metronidazole regimen, has been reported as 50%-83.3% in retrospective studies[20, 21] and 54-58% in prospective studies[11,14,18]. A longer 14 d regimen also resulted in a low success rate at 63.6%[23]. The European Registry on *H.pylori* management (Hp-EuReg) has provided the largest experience of treatment in penicillin allergic patients[25]. Although drug dose, frequency and duration details were not provided, the PPI-Clarithromycin-Metronidazole regimen achieved 69% success rate. Two studies from Japan, have shown higher success rates (92.3%-100%) for this 7 d triple therapy when combined with Vonoprazan (a potassium-competitive blocker that inhibits gastric H+K+-ATPase) instead of a PPI[20,21].

In a prospective study, Rodriguez-Torres *et* *al* reported a success rate of 85% with a 10 d triple therapy combining Esomeprazole, Tetracycline and Metronidazole[12]. A small retrospective study from Japan also reported a similar success rate of 80% when this regimen was used for 7-14 ds[13]. Osumi *et* *al* achieved a 100% success rate using a modified 7 d regimen, substituting Minocycline for Tetracycline in a small study of 5 patients[22].

Levofloxacin in combination with Clarithromycin and PPI has been reported to achieve an 80% success rate[25]. Recent studies from Japan have evaluated treatment regimens utilising the fluoroquinolone, Sitafloxacin, which has a lower minimum inhibitory concentration for *H.pylori* than Levofloxacin and is effective in strains with the gyrA mutation, which denotes resistance to Levofloxacin[19]. Remarkably high success rates of 100% were reported for 7-14 d treatment regimens combining Sitafloxacin with Metronidazole and PPI, in two retrospective[17,20] and one prospective study[19].

**Quadruple therapy:** Retrospective data has demonstrated a 91% success rate for the PPI-Bismuth-Tetracycline-Metronidazole quadruple therapy[25]. Three prospective studies have reported success rates of 74% with a 10 d PPI-Bismuth-Tetracycline-Metronidazole combination[18], 84.8% with a 14 d PPI-Bismuth-Clarithromycin-Metronidazole regimen[23] and 85.5% with a 14 d PPI-Bismuth-Levofloxacin-Cefuroxime treatment[24].

***Second line therapy***

In view of the attrition of successfully treated patients with each course of treatment, patient numbers for studies evaluating second line therapies tend to be low, often in single digits[12,17,20].

**Triple therapy:** Gisbert *et* *al*[14,18] have treated a relatively large number of patients with a 10 d combination of PPI-Clarithromycin-Levofloxacin, demonstrating success rates of 64%-73%. Levofloxacin based triple therapy using Clarithromycin or Metronidazole appears to achieve similar success rates, of 75% and 76.5%, respectively[25]. Sitafloxacin-based triple therapy has shown success rates of 100% in 2 small retrospective studies evaluating a 7 d regimen[17,20], whilst a prospective study investigating a 10 d treatment course reported a lower success rate of 84.2%[19]. Sue *et* *al* demonstrated a success rate of 88.2% in a prospective study of a 7 d Sitafloxacin regimen using Vonoprazan instead of a PPI[27].

**Quadruple therapy:** An early study from Spain reported a low success rate of 47% using a 7 d regimen of Ranitidine Bismuth citrate-Tetracycline-Metronidazole, which has been considered as quadruple therapy due to an acid-suppressing agent and bismuth being combined into one tablet[11]. The same group of investigators also reported a low success rate of 37% for 10 d PPI-Bismuth-Tetracycline-Metronidazole quadruple therapy[18]. However, the European Registry has demonstrated a success rate of 78.3% for this regimen[25]. In a large prospective study, Liang *et* *al*[16] included 109 penicillin allergic patients randomised to 2 wk quadruple therapy with either PPI-Bismuth-Tetracycline-Metronidazole or PPI-Bismuth-Tetracycline-Furazolidine; success rates were 87.9% and 91.7%, with no difference between penicillin allergic and non-allergic patients[16].

A relatively large study from Australia reported on 69 patients with penicillin allergy, who had all failed prior therapy with PPI-Clarithromycin-Metronidazole. Treatment with a 10 d regimen of PPI-Bismuth subcitrate-Rifabutin-Ciprofloxacin achieved a success rate of 94.2%[15].

Luo *et* *al*[26] prospectively evaluated an antibiotic susceptibility approach using a variety of 14 d quadruple therapies, and demonstrated high success rates of 80%-100%. However, the results were not presented separately for first-line and rescue treatments[26].

***Salvage (third-line) therapy***

The published data for salvage therapy after failure of second-line treatment is very limited with 4 studies reporting on patient numbers in single figures[11,17-19]. Details are provided in the Table but it is difficult to draw any meaningful conclusions from the results.

**Evidence from non-penicillin combination regimes in unselected groups of patients:** Meta-analyses of trials on the efficacy of non-penicillin regimes in treating *H.pylori* infection are an alternate source of useful information when making treatment decisions about penicillin allergic individuals. These trials generally included unselected group of individuals without considering penicillin allergy status.

The meta-analysis by Gisbert *et* *al*[28] demonstrated a success rate of 81% with 7 d triple therapy regimen of PPI-Clarithromycin -Nitroimidazole, similar to the success rate with the regimen containing amoxicillin instead of nitroimidazole.

Two meta-analyses of randomised controlled trials on first line therapy of *H.pylori* with quadruple therapy of PPI-Bismuth-Tetracycline-Metronidazole have shown success rates of 77%[29,30]. A longer duration (10-14 d) of quadruple therapy was more effective than the 7 d triple therapy of PPI-Clarithromycin-Amoxicillin[30].

**SUMMARY** **AND** **RECOMMENDATIONS**

The triple therapy regimen of PPI-Clarithromycin-Metronidazole is still frequently used as first line therapy for penicillin allergic subjects[25]. However, whilst it demonstrates an acceptable success rate of approximately 80% in unselected patients[28], it does not perform well in penicillin allergic patients[11,14,18,20,21,23,25]. The reasons for this discrepancy are unclear, but it is possible is that the studies of unselected patients may only have had small numbers of penicillin allergic individuals, or the study design may have excluded individuals with antibiotic allergy. Whilst there is a paucity of recent data for this specific regimen, the efficacy of Clarithromycin-based triple therapy has been shown to be significantly impaired in the presence of Clarithromycin resistance, which is an increasingly encountered issue[29]. Whilst increasing the duration of PPI-Amoxicillin-Clarithromycin triple therapy has been shown to improve success rates, this has not been demonstrated convincingly for the PPI-Clarithromycin-Metronidazole regimen[31]. If available, Vonoprazan could be considered as a substitute for PPI in clarithromycin-based triple therapy to improve its efficacy[20,21]. Sitafloxacin-based triple therapy is an alternative option, although this antibiotic is not widely available[17,19,20]. Bismuth-based quadruple therapy, lasting 10-14 d, is the most attractive option for first-line treatment of *H.pylori*, with a high success rate in patients with penicillin allergy[18,23,24,25], matching that in unselected patients[29,30]. In order to optimise the success of first line treatment, a detailed history of prior antibiotic use could aid the choice of regimen prescribed.

In the event of treatment failure, the published evidence suggests that second-line therapy should be instituted with the 10 d PPI-Levofloxacin-Clarithromycin regimen[14,18]; a Sitafloxacin-based triple therapy is an alternative option[17,19,20,27] . If Bismuth-based quadruple therapy has not been used as first-line treatment, then this regime could be considered for subsequent treatment, although there is variable evidence for the efficacy of PPI-Bismuth-Tetracycline-Metronidazole quadruple therapy[16,18,25]. Alternative antibiotic combinations may be more successful such as PPI-Bismuth-Tetracycline-Furazolidine[16] or PPI-Bismuth-Rifabutin-Ciprofloxacin[15], although there are concerns about the potential for side-effects with rifabutin, especially myelotoxicity[32].

It is not possible to provide any evidence-based recommendations for salvage therapy after failure of two treatment courses. It is generally recommended that in this situation, further treatment should be guided by the results of *H.pylori* culture and sensitivity testing[5,6,26]. Another approach is to confirm penicillin allergy at this stage, as many patients with this label turn out not to be truly allergic[5,6,9]. A negative penicillin skin test allows the safe use of amoxicillin-containing salvage regimens, as recommended for non-allergic patients.

**CONCLUSION**

This review of the evidence for treating *H.pylori* in penicillin-allergic individuals has highlighted the lack of high-quality studies to help guide management strategies. Whilst recommendations have been made based on the limited data, it would be important to monitor the success of treatment regimens and use what can be demonstrated to be effective locally[33]. Regional differences in drug availability will influence the choice of regimen, and patterns of antibiotic resistance rates will influence treatment success.

**REFERENCES**

1 **Peleteiro** **B**, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. *Dig* *Dis* *Sci* 2014; **59**: 1698-1709 [PMID: 24563236 DOI: 10.1007/s10620-014-3063-0]

2 **NIH** **Consensus** **Conference**. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. *JAMA* 1994; **272**: 65-69 [PMID: 8007082]

3 **IARC** **Working** **Group** **on** **the** **Evaluation** **of** **Carcinogenic** **Risks** **to** **Humans**. Biological agents. Volume 100 B. A review of human carcinogens. *IARC* *Monogr* *Eval* *Carcinog* *Risks* *Hum* 2012; **100**: 1-441 [PMID: 23189750]

4 **NICE** **clinical** **guideline**. Gastro-oesophageal reflex disease and dyspepsia in adults: investigation and management (2014). [cited 20 February 2021]. Available from: https://www.nice.org.uk/guidance/cg184/chapter/1-recommendations

5 **Chey** **WD**, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am* *J* *Gastroenterol* 2017; **112**: 212-239 [PMID: 28071659 DOI: 10.1038/ajg.2016.563]

6 **Malfertheiner** **P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]

7 **Liu** **WZ**, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. *Helicobacter* 2018; **23**: e12475 [PMID: 29512258 DOI: 10.1111/hel.12475]

8 **Thung** **I**, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. *Aliment* *Pharmacol* *Ther* 2016; **43**: 514-533 [PMID: 26694080 DOI: 10.1111/apt.13497]

9 **Blumenthal** **KG**, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. *Lancet* 2019; **393**: 183-198 [PMID: 30558872 DOI: 10.1016/S0140-6736(18)32218-9]

10 **Prach** **AT**, Malek M, Tavakoli M, Hopwood D, Senior BW, Murray FE. H2-antagonist maintenance therapy *vs* Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study. *Aliment* *Pharmacol* *Ther* 1998; **12**: 873-880 [PMID: 9768530 DOI: 10.1046/j.1365-2036.1998.00391.x]

11 **Gisbert** **JP**, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. *Aliment* *Pharmacol* *Ther* 2005; **22**: 1041-1046 [PMID: 16268980 DOI: 10.1111/j.1365-2036.2005.02687.x]

12 **Rodríguez-Torres** **M**, Salgado-Mercado R, Ríos-Bedoya CF, Aponte-Rivera E, Marxuach-Cuétara AM, Rodríguez-Orengo JF, Fernández-Carbia A. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. *Dig* *Dis* *Sci* 2005; **50**: 634-639 [PMID: 15844694 DOI: 10.1007/s10620-005-2549-1]

13 **Matsushima** **M**, Suzuki T, Kurumada T, Watanabe S, Watanabe K, Kobayashi K, Deguchi R, Masui A, Takagi A, Shirai T, Muraoka H, Kobayashi I, Mine T. Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection. *J* *Gastroenterol* *Hepatol* 2006; **21**: 232-236 [PMID: 16460479 DOI: 10.1111/j.1440-1746.2006.04171.x]

14 **Gisbert** **JP**, Pérez-Aisa A, Castro-Fernández M, Barrio J, Rodrigo L, Cosme A, Gisbert JL, Marcos S, Moreno-Otero R. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. *Dig* *Liver* *Dis* 2010; **42**: 287-290 [PMID: 19632166 DOI: 10.1016/j.dld.2009.06.007]

15 **Tay** **CY**, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. *Aliment* *Pharmacol* *Ther* 2012; **36**: 1076-1083 [PMID: 23072648 DOI: 10.1111/apt.12089]

16 **Liang** **X**, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. *Clin* *Gastroenterol* *Hepatol* 2013; **11**: 802-7.e1 [PMID: 23376004 DOI: 10.1016/j.cgh.2013.01.008]

17 **Furuta** **T**, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, Kagami T, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. *Intern* *Med* 2014; **53**: 571-575 [PMID: 24633026 DOI: 10.2169/internalmedicine.53.1677]

18 **Gisbert** **JP**, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L, Cosme A, Gisbert JL, Fernández-Bermejo M, Marcos S, Marín AC, McNicholl AG. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. *Dig* *Dis* *Sci* 2015; **60**: 458-464 [PMID: 25236423 DOI: 10.1007/s10620-014-3365-2]

19 **Mori** **H**, Suzuki H, Matsuzaki J, Masaoka T, Kanai T. Antibiotic resistance and *gyrA* mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for *Helicobacter* *pylori* in penicillin allergic patients. *United* *European* *Gastroenterol* *J* 2017; **5**: 796-804 [PMID: 29026593 DOI: 10.1177/2050640616688995]

20 **Ono** **S**, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. *Helicobacter* 2017; **22** [PMID: 28098408 DOI: 10.1111/hel.12374]

21 **Sue** **S**, Suzuki N, Shibata W, Sasaki T, Yamada H, Kaneko H, Tamura T, Ishii T, Kondo M, Maeda S. First-Line *Helicobacter* *pylori* Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin. *Gastroenterol* *Res* *Pract* 2017; **2017**: 2019802 [PMID: 29181022 DOI: 10.1155/2017/2019802]

22 **Osumi** **H**, Fujisaki J, Suganuma T, Horiuchi Y, Omae M, Yoshio T, Ishiyama A, Tsuchida T, Miki K. A significant increase in the pepsinogen I/II ratio is a reliable biomarker for successful Helicobacter pylori eradication. *PLoS* *One* 2017; **12**: e0183980 [PMID: 28854276 DOI: 10.1371/journal.pone.0183980]

23 **Long** **X**, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. *Helicobacter* 2018; **23**: e12485 [PMID: 29696736 DOI: 10.1111/hel.12485]

24 **Song** **Z**, Fu W, Zhou L. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin. *BMC* *Gastroenterol* 2019; **19**: 132 [PMID: 31345165 DOI: 10.1186/s12876-019-1056-3]

25 **Nyssen** **OP**, Pérez-Aisa Á, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Brglez Jurecic N, Huguet JM, Alcaide N, Voynovan I, María Botargues Bote J, Modolell I, Pérez Lasala J, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Marcos Pinto R, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, Boyanova L, Shvets O, Venerito M, Bytzer P, Goldis A, Simsek I, Lamy V, Przytulski K, Kunovský L, Capelle L, Milosavljevic T, Caldas M, Garre A, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on *H.pylori* management (Hp-EuReg). *Helicobacter* 2020; **25**: e12686 [PMID: 32173974 DOI: 10.1111/hel.12686]

26 **Luo** **L**, Huang Y, Liang X, Ji Y, Yu L, Lu H. Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies. *Helicobacter* 2020; **25**: e12699 [PMID: 32428369 DOI: 10.1111/hel.12699]

27 **Sue** **S**, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S. *Helicobacter* *pylori* rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy. *JGH* *Open* 2021; **5**: 307-311 [PMID: 33553672 DOI: 10.1002/jgh3.12492]

28 **Gisbert** **JP**, González L, Calvet X, García N, López T, Roqué M, Gabriel R, Pajares JM. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. *Aliment* *Pharmacol* *Ther* 2000; **14**: 1319-1328 [PMID: 11012477 DOI: 10.1046/j.1365-2036.2000.00844.x]

29 **Luther** **J**, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. *Am* *J* *Gastroenterol* 2010; **105**: 65-73 [PMID: 19755966 DOI: 10.1038/ajg.2009.508]

30 **Venerito** **M**, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy *vs* clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. *Digestion* 2013; **88**: 33-45 [PMID: 23880479 DOI: 10.1159/000350719]

31 **Yuan** **Y**, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for Helicobacter pylori eradication. *Cochrane* *Database* *Syst* *Rev* 2013: CD008337 [PMID: 24338763 DOI: 10.1002/14651858.CD008337.pub2]

32 **Gisbert** **JP**, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. *Aliment* *Pharmacol* *Ther* 2012; **35**: 209-221 [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x]

33 **Graham** **DY**, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. *Gut* 2010; **59**: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]

**Footnotes**

**Conflict-of-interest** **statement:** The authors have no conflicts of interest to declare

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript** **source:** Invited manuscript

**Corresponding** **Author's** **Membership** **in** **Professional** **Societies:** British Society of Gastroenterology, BSG63939; American Gastroenterological Association, 982600.

**Peer-review** **started:** April 12, 2021

**First** **decision:** June 3, 2021

**Article** **in** **press:**

**Specialty** **type:** Gastroenterology and hepatology

**Country/Territory** **of** **origin:** United Kingdom

**Peer-review** **report’s** **scientific** **quality** **classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cheng H, El-Bendary M, Ma H **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Table** **1** **Published** **studies** **of** ***Helicobacter*** ***pylori*** **eradication** **therapy** **in** **patients** **allergic** **to** **penicillin**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Yr** |  **Country** | **Study** **type** | **Treatment** **details** | ***n*** | **Success** **rate** **(PP, %)** | **Success** **rate** **(ITT, %)** |
| Prach *et* *al*[10] | 1998 | United Kingdom | Prospective,single cohort | *1st* *line* O 20 mg b.d., C 500 mg t.d.s, 14 ds | 3 | 100;  | 100;  |
| Gisbert *et* *al*[11]  | 2005 | Spain | Prospective, single cohort | *1st* *line* O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; *2nd* *line* RBC 400 mg b.d., T 500 mg q.d.s., M 250 mg q.d.s., 7 d; *3rd* *line* O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; *4th* *line* O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 ds  | 12; 17; 9; 2 | 64; 53; 17; 100 | 58; 47; 11; 100 |
| Rodriguez-Torres *et* *al*[12] | 2005 | Puerto Rico | Prospective, single cohort | *1st* *line* E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d; *2nd* *line* E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d | 17; 3 | NA; NA | 85; 100  |
| Matsushima *et* *al*[13] | 2006 | Japan | Retrospective, single cohort | *1st* *line* PPI o.d., T 500 mg b.d., M 250 mg b.d., 7-14 d | 5 | 100  | 80  |
| Gisbert *et* *al*[14] | 2010 | Spain | Prospective, single cohort | *1st* *line* O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; *2nd* *line* O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d | 50; 15 | 55; 73 | 54; 73 |
| Tay *et* *al*[15] | 2012 | Australia | Prospective, single cohort | *2nd* *line* R 20 mg t.d.s., B 240 mg q.d.s., RIF 150 mg b.d., CF 500 mg b.d., 10 d | 69 | 94.2  | 94.2  |
| Liang *et* *al*[16] | 2013 | China | Prospective, randomised | *2nd* *line* 109 pen allergic overall but results reported for whole group including non-allergic; L 30 mg b.d., B 220 mg b.d., T 500 mg t.d.s., F 100 mg t.d.s., 14 d; L 30 mg b.d., B 220 mg b.d., T 500 mg q.d.s., M 400 mg q.d.s., 14 d | 108; 107 | 96.1; 93.1  | 91.7; 87.9  |
| Furuta *et* *al*[17] | 2014 | Japan | Retrospective, single cohort | *1st* *line* PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; *1st* *line* PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; *2nd* *Line* PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; *2nd* *Line* PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; *3rd* *Line* PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; *3rd* *Line* PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d | 7; 4; 9; 3; 3; 2 | 100; 100; 100; 100; 100; 100  | 100; 100; 100; 100; 100; 100  |
| Gisbert *et* *al*[18] | 2015 | Spain | Prospective, single cohort | *1st* *line* O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; *2nd* *line* O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; *3rd* *line* O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; *4th* *line* O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; *3rd* *line* O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d;  4th line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; *2nd* *line* O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; *3rd* *line* O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; *1st* *line* O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d;  *2nd* *line* O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d | 112; 24; 3; 2; 7; 2; 50; 3; 50; 14 | 59; 38; 50; 0; 20; 100; 73; 100; 75; 64;  | 57; 37; 33; 50; 14; 100; 64; 100; 74; 64;  |
| Mori *et* *al*[19] | 2017 | Japan | Prospective, single cohort | *1st* *line* E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; *2nd* *line* E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; *3rd* *line* E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d | 33; 19; 5 | 100; 84.2; 40  | 100; 84.2; 40  |
| Ono *et* *al*[20] | 2017 | Japan | Retrospective,single cohort | *1st* *line* PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; *1st* *line* V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; *1st* *line* PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; *1st* *line* V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; *2nd* *line* PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; *2nd* *line* V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; *2nd* *line* PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; *2nd* *line* V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d | 10; 13; 20; 14; 3; 1; 24; 3 | 55.6; 92.3; 100; 100; 33.3; 100; 100; 66.7 | 50; 92.3; 100; 92.9; 33.3; 100; 100; 66.7  |
| Sue *et* *al*[21] | 2017 | Japan | Prospective& retrospective, single cohort | *1st**line* V 20 mg b.d., C 200 or 400 mg b.d., M 250 mg b.d., 7 d; *1st**line* PPI b.d, C 200 or 400 mg b.d, M 750 mg b.d., 7 d  | 20; 30 | 100; 86.2  | 100; 83.3  |
| Osumi *et* *al*[22] | 2017 | Japan | Prospective, single cohort | *1st* *line* R 20 mg b.d, Mi 100 mg b.d, M 250 mg b.d., 7 d | 5 | 100  | 100  |
| Long *et* *al*[23] | 2018 | China | Prospective, randomised | *1st* *line* E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; *1st* *line* E 20 mg b.d., B 600 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d | 33; 33 | 70; 96  | 63.6; 84.8  |
| Song *et* *al*[24] | 2019 | China | Prospective, single cohort | *1st* *line* E 20 mg b.d, B 220 mg b.d., LF 500 mg o.d., Cef 500 mg b.d., 14 d | 152 | 90.1  | 85.5 |
| Nyssen *et* *al*[25] | 2020 | Europe | Retrospective,multi-centre registry | *1st* *line* PPI, C, M; *1st* *line* PPI, C, LF; *1st* *line* PPI, B, T, M; *2nd* *line* PPI, C, LF; *2nd* *line* PPI, M, LF; *2nd* *line* PPI, B, T, M; *3rd* *line* PPI, B, T, M; *3rd* *line* PPI, B, C, LF; *3rd* *line* PPI, C, LF *(NB* *drug* *dose,* *frequency* *and* *duration* *not* *specified)* | 285; 54; 250; 20; 13; 70; 18; 1; 2 | 69; 82; 92; 73.7; 76.5; 81.8; 77.8; 100; 50  | 69; 80; 91; 75; 76.5; 78.3; 77.8; 100; 50  |
| Luo *et* *al*[26] | 2020 | China | Prospective, single cohort | *1st* *&* *2nd* *line* E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; *1st* *&* *2nd* *line* E20 mg b.d., B 220 mg b.d., C 500 mg b.d., M 400 mg q.d.s., 14 d; *1st* *&* *2nd* *line* E 20 mg b.d., LF 500 mg o.d., M 400 mg b.d., 14 d; *1st* *&* *2nd* *line* E 20 mg b.d., B 220 mg b.d, LF 500 mg o.d., M 400 mg q.d.s., 14 d; *1st* *&* *2nd* *line* E 20 mg b.d., T 500 mg q.d.s., M 400 mg b.d., 14 d; *1st* *&* *2nd* *line* E 20 mg b.d., B 220 mg b.d, T 500 mg q.d.s., M 400 mg q.d.s., 14 d | 5; 22; 1; 10; 2; 72 | 100; 94.1; 100; 100; 100; 100  | 100; 81.8; 100; 80; 100; 97.2  |
| Sue *et* *al*[27] | 2021 | Japan | Prospective, single cohort | *2nd* *line* V 20 mg b.d,, SF 100 mg b.d., M 250 mg b.d., 7 d | 17 | 88.2  | 88.2 |

PP: Per protocol analysis; ITT: Intention to treat analysis; B: Bismuth compound; C: Clarithromycin; Cef: Cefuroxime; CF: Ciprofloxacin; E: Esomeprazole F: Furazolidone; LF: Levofloxacin; M: Metronidazole; Mi: minocycline O: Omeprazole; PPI: proton pump inhibitor; R: Rabeprazole; RBC: ranitidine bismuth subcitrate; RIF: Rifabutin; SF: Sitafloxacin; T: Tetracycline; V: Vonoprazan.